Should I buy or sell G1 Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks .

What is G1 Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued 12 month price targets for G1 Therapeutics' shares. Their GTHX share price targets range from $5.00 to $19.00. On average, they predict the company's share price to reach $11.80 in the next year. This suggests a possible upside of 490.0% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts .

How have GTHX shares performed in 2023?

G1 Therapeutics' stock was trading at $5.43 at the beginning of the year. Since then, GTHX stock has decreased by 63.2% and is now trading at $2.00. View the best growth stocks for 2023 here .

When is G1 Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our GTHX earnings forecast .

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. The business had revenue of $12.30 million for the quarter, compared to the consensus estimate of $13.73 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 132.03% and a negative net margin of 90.82%.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX) , Sorrento Therapeutics (SRNE) , ImmunoGen (IMGN) , Inovio Pharmaceuticals (INO) , Johnson & Johnson (JNJ) , Gilead Sciences (GILD) , Kadmon (KDMN) , VBI Vaccines (VBIV) , Novavax (NVAX) and Pfizer (PFE) .

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Raymond James & Associates (1.79%), Jacobs Levy Equity Management Inc. (1.11%), Connor Clark & Lunn Investment Management Ltd. (0.39%), Denali Advisors LLC (0.29%), Acadian Asset Management LLC (0.25%) and Franklin Street Advisors Inc. NC (0.16%). Insiders that own company stock include Andrew Perry, James S Hanson , Jennifer K Moses, John E (Jack) Jr Bailey , Mark A Velleca, Mark A Velleca , Rajesh Malik , Seth Rudnick and Terry L Murdock. View institutional ownership trends .

How do I buy shares of G1 Therapeutics?

Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

G1 Therapeutics Stock Price, News & Analysis (NASDAQ:GTHX)

$2.00

+0.12 (+6.38%)

(As of 12/1/2023 ET)

Compare

Today's Range: $1.80
▼
$2.01
50-Day Range: $1.12
▼
$2.00
52-Week Range: $1.08
▼
$8.40

Volume: 1.13 million shs
Average Volume: 480,939 shs
Market Capitalization: $103.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.80

G1 Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 490.0% Upside
$11.80 Price Target
Short Interest: Bearish
4.80% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -2.45
Upright™ Environmental Score
News Sentiment: 0.02
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.96) to ($0.82) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

725th out of 955 stocks

Pharmaceutical Preparations Industry

347th out of 446 stocks

3.3

Analyst's Opinion

Consensus Rating
G1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 5 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $11.80, G1 Therapeutics has a forecasted upside of 490.0% from its current price of $2.00.
Amount of Analyst Coverage
G1 Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.80% of the outstanding shares of G1 Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
G1 Therapeutics has a short interest ratio ("days to cover") of 4.8.
Change versus previous month
Short interest in G1 Therapeutics has recently increased by 2.05%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
G1 Therapeutics does not currently pay a dividend.
Dividend Growth
G1 Therapeutics does not have a long track record of dividend growth.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
G1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for G1 Therapeutics is -2.45.

1.7

News and Social Media Coverage

News Sentiment
G1 Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for G1 Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 5 people have searched for GTHX on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, G1 Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 8.23% of the stock of G1 Therapeutics is held by insiders.
Percentage Held by Institutions
Only 30.04% of the stock of G1 Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for G1 Therapeutics are expected to grow in the coming year, from ($0.96) to ($0.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of G1 Therapeutics is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of G1 Therapeutics is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
G1 Therapeutics has a P/B Ratio of 2.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About G1 Therapeutics Stock (NASDAQ:GTHX)

G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

GTHX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

GTHX Stock News Headlines

November 29, 2023 | finance.yahoo.com

G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium

November 11, 2023 | finance.yahoo.com

When Will G1 Therapeutics, Inc. (NASDAQ:GTHX) Turn A Profit?

December 3, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

November 3, 2023 | bizjournals.com

Chemotherapy shortage slams RTP firm's revenue projections

November 2, 2023 | nasdaq.com

G1 Therapeutics (GTHX) Price Target Increased by 7.95% to 9.69

November 2, 2023 | finance.yahoo.com

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q3 2023 Earnings Call Transcript

November 1, 2023 | finance.yahoo.com

G1 Therapeutics Inc (GTHX) Reports Q3 2023 Earnings: $12.3 Million in Total Revenue

November 1, 2023 | finance.yahoo.com

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

December 3, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

October 31, 2023 | benzinga.com

Earnings Preview For G1 Therapeutics

October 31, 2023 | msn.com

G1 Therapeutics Q3 2023 Earnings Preview

October 27, 2023 | finance.yahoo.com

Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

October 25, 2023 | finance.yahoo.com

Will G1 Therapeutics (GTHX) Report Negative Earnings Next Week? What You Should Know

October 18, 2023 | finance.yahoo.com

G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023

October 18, 2023 | finance.yahoo.com

G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)

October 16, 2023 | finance.yahoo.com

G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium

October 7, 2023 | msn.com

JP Morgan Downgrades G1 Therapeutics (GTHX)

October 6, 2023 | msn.com

G1 Therapeutics downgraded at JPMorgan on potential Q3 miss

September 5, 2023 | finance.yahoo.com

G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 4, 2023 | msn.com

Wedbush Reiterates G1 Therapeutics (GTHX) Outperform Recommendation

August 3, 2023 | msn.com

Needham Maintains G1 Therapeutics (GTHX) Buy Recommendation

August 2, 2023 | finance.yahoo.com

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

August 1, 2023 | markets.businessinsider.com

G1 Therapeutics earnings: here's what Wall Street expects

July 31, 2023 | finance.yahoo.com

G1 Therapeutics to Participate in Two August Investor Conferences

July 31, 2023 | finance.yahoo.com

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

July 27, 2023 | finance.yahoo.com

G1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are individual investors with 46% stake, while 38% is held by institutions

July 26, 2023 | finance.yahoo.com

G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023

See More Headlines

Receive GTHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 12/03/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/06/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GTHX
CUSIP: N/A
CIK: 1560241
Web: www.g1therapeutics.com
Phone: (919) 213-9835
Fax: 919-741-5830
Employees: 170
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.80
High Stock Price Target: $19.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +490.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-147,560,000.00
Net Margins: -90.82%
Pretax Margin: -87.36%
Return on Equity: -132.03%
Return on Assets: -44.85%

Debt

Debt-to-Equity Ratio: 1.19
Current Ratio: 3.75
Quick Ratio: 3.35

Sales & Book Value

Annual Sales: $51.30 million
Price / Sales: 2.02
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.83 per share
Price / Book: 2.41

Miscellaneous

Outstanding Shares: 51,840,000
Free Float: 47,577,000
Market Cap: $103.68 million
Optionable: Optionable
Beta: 1.81

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. John E. Bailey Jr. (Age 58)
CEO, President & Director
Comp: $1.06M
Mr. Mark Avagliano (Age 47)
Chief Business Officer
Comp: $628.54k
Mr. John W. Umstead V (Age 38)
Chief Financial Officer
Mr. Terry L. Murdock (Age 63)
Chief Operating Officer
Comp: $541.59k
Mr. William C. Roberts (Age 54)
Vice President of Investor Relations & Corporate Communications
Ms. Monica R. Thomas
General Counsel & Chief Compliance Officer
Mr. Evan Hicks M.B.A.
Vice President of Marketing
Dr. Rajesh K. Malik Ch.B. (Age 64)
M.B., M.D., Chief Medical Officer
Comp: $596.37k
Mr. Andrew Perry (Age 50)
Chief Commercial Officer
Comp: $568.6k
Mr. Jeff Macdonald
Senior Director of Investor Relations & Corporate Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GTHX Stock Analysis - Frequently Asked Questions

Should I buy or sell G1 Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GTHX shares.
View GTHX analyst ratings or view top-rated stocks.
What is G1 Therapeutics' stock price target for 2024?: 6 Wall Street research analysts have issued 12 month price targets for G1 Therapeutics' shares. Their GTHX share price targets range from $5.00 to $19.00. On average, they predict the company's share price to reach $11.80 in the next year. This suggests a possible upside of 490.0% from the stock's current price.
View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts.
How have GTHX shares performed in 2023?: G1 Therapeutics' stock was trading at $5.43 at the beginning of the year. Since then, GTHX stock has decreased by 63.2% and is now trading at $2.00.
View the best growth stocks for 2023 here.
When is G1 Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our GTHX earnings forecast.
How were G1 Therapeutics' earnings last quarter?: G1 Therapeutics, Inc. (NASDAQ:GTHX) released its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. The business had revenue of $12.30 million for the quarter, compared to the consensus estimate of $13.73 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 132.03% and a negative net margin of 90.82%.

What other stocks do shareholders of G1 Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).
When did G1 Therapeutics IPO?: (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
Who are G1 Therapeutics' major shareholders?: G1 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Raymond James & Associates (1.79%), Jacobs Levy Equity Management Inc. (1.11%), Connor Clark & Lunn Investment Management Ltd. (0.39%), Denali Advisors LLC (0.29%), Acadian Asset Management LLC (0.25%) and Franklin Street Advisors Inc. NC (0.16%). Insiders that own company stock include Andrew Perry, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock.
View institutional ownership trends.
How do I buy shares of G1 Therapeutics?: Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:GTHX) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial